diabetes

Showing 15 posts of 392 posts found.

Novo Nordisk to cut 2% of its entire workforce

September 29, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Denmark, Novo Nordisk, diabetes, insulin, job cuts, job losses

Novo Nordisk, headquartered in Bagsvaerd, Denmark, has taken the decision to lose 1,000 of its workforce from a total global …

Novo Nordisk to provide discounted insulin to poorest nations

September 23, 2016
Medical Communications, Sales and Marketing Novo Nordisk, diabetes, insulin

Danish pharma firm Novo Nordisk has announced its intention to provide insulin at discounted prices to the world’s poorest nations …

Novo Nordisk’s diabetes drug “significantly reduced’ cardiovascular risk

September 16, 2016
Medical Communications Novo Nordisk, diabetes, semaglutide

Novo Nordisk has announced that its diabetes drug semaglutide “significantly reduced” the risk of major cardiovascular events at the 52nd …

Sanofi and Google forge $500 million diabetes partnership

September 12, 2016
Research and Development, Sales and Marketing Alphabet, Sanofi, Verily, diabetes, google

Sanofi is set to join forces with Alphabet’s life sciences firm Verily in a $500 million partnership to develop diabetes …

Roche launches ‘next-generation’ blood glucose monitoring system

August 23, 2016
Manufacturing and Production, Sales and Marketing Roche, blood glucose monitoring, diabetes

Roche has announced the launch of its new Accu-Chek Guide blood glucose monitoring system. The system promises to simplify everyday …

FDA delays appraisal of Sanofi, Zealand diabetes drug just days before decision due

August 22, 2016
Research and Development, Sales and Marketing NDA, Sanofi, appraisal, diabetes, iglarlixi, type 2, type-2, zealand

There was unfortunate news for Sanofi and Zealand Pharma as the FDA announced that it required additional information, constituting a …

Promising results for new type 2 diabetes management procedure

August 12, 2016
Research and Development, Sales and Marketing Fractyl, Revita, diabetes, type 2 diabetes

Fractyl Laboratories has revealed data from its first-in-human study of Revita duodenal mucosal resurfacing (Revita DMR), a new 60-minute, non-surgical …

Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk

August 5, 2016
Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure

Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …

Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin

July 28, 2016
Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand

Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …

Eli Lilly says FDA panel backs approval of Jardiance for cardiovascular indication

June 30, 2016
Research and Development, Sales and Marketing Eli Lilly, cardiovascular, diabetes, jardiance

US drugmaker Eli Lilly (NYSE: LLY) said a US regulatory panel has backed its Jardiance (empagliflozin) for reducing cardiovascular death …

Lilly showcases positive late-stage data in diabetes treatments

June 13, 2016
Research and Development, Sales and Marketing diabetes, lilly

Eli Lilly (NYSE: LLY) has presented data on their diabetes drugs in late-stage trials at the 76th American Diabetes Association …

FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug

June 1, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, diabetes, jentadueto, jentadueto xr, lilly, partnership, type 2, type-2

The US Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release) tablets for the …

Nice recommends three drugs to treat diabetes

May 25, 2016
Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes

The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …

US FDA advisors question usefulness of Sanofi’s combination diabetes therapy

May 24, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, US FDA, diabetes, drug trial, regulation

US Food and Drug Administration staff questioned the benefits of French drugmaker Sanofi’s (Euronext: SAN) diabetes drug candidate as well …

Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure

April 20, 2016
Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly

Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …

The Gateway to Local Adoption Series

Latest content